<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27817774</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1008-8830</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>11</Issue><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics</Title><ISOAbbreviation>Zhongguo Dang Dai Er Ke Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Expression of vasoactive intestinal peptide in peripheral blood of children with hand, foot and mouth disease].</ArticleTitle><Pagination><StartPage>1106</StartPage><EndPage>1110</EndPage><MedlinePgn>1106-1110</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the expression of vasoactive intestinal peptide (VIP) in peripheral blood of children with hand, foot and mouth disease and its significance.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">According to the condition of the disease, 86 children with hand, foot and mouth disease were classified into phase 1 group (19 children) and phase 2 group (67 children). ELISA was used to measure the concentrations of plasma VIP, interferon-&#x3b3; (IFN-&#x3b3;), and interleukin-4 (IL-4) in peripheral blood. Flow cytometry was used to measure CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> T lymphocyte subsets. RT-PCR was used for qualitative detection of enterovirus 71 (EV71) RNA in stool.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with the phase 1 group, the phase 2 group had a significantly higher positive rate of EV71-RNA (P&lt;0.05) and significantly higher serum levels of IgG, IgA, IgM, and C3 (P&lt;0.05). The phase 2 group had significantly lower proportions of peripheral CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> T lymphocyte subsets than the phase 1 group (P&lt;0.05), as well as significantly lower proportion of peripheral B cells and CD4<sup>+</sup>/CD8<sup>+</sup> ratio than the phase 1 group (P&lt;0.05). The phase 2 group also had a significantly lower concentration of VIP in peripheral blood than the phase 1 group (P&lt;0.05). In the 86 children with hand, foot and mouth disease, the concentration of VIP in peripheral blood was positively correlated with the proportion of CD4<sup>+</sup> T lymphocyte subset and CD4<sup>+</sup>/CD8<sup>+</sup> ratio (r=0.533 and 0.532 respectively; P&lt;0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">VIP may be an important marker of the severity of hand, foot and mouth disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Jin-Song</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Infecious Disease, Xuzhou Children's Hospital, Xuzhou, Jiangsu 221002, China. wamhm@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Hao-Miao</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Jing-De</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Cheng</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Dai-Hua</ForeName><Initials>DH</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhongguo Dang Dai Er Ke Za Zhi</MedlineTA><NlmUniqueID>100909956</NlmUniqueID><ISSNLinking>1008-8830</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508598">IL4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical><Chemical><RegistryNumber>37221-79-7</RegistryNumber><NameOfSubstance UI="D014660">Vasoactive Intestinal Peptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016516" MajorTopicYN="N">CD4-CD8 Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014660" MajorTopicYN="N">Vasoactive Intestinal Peptide</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText Label="&#x76ee;&#x7684;">&#x521d;&#x6b65;&#x63a2;&#x8ba8;&#x624b;&#x8db3;&#x53e3;&#x75c5;&#x60a3;&#x513f;&#x5916;&#x5468;&#x8840;&#x8840;&#x7ba1;&#x6d3b;&#x6027;&#x80a0;&#x80bd;&#x7684;&#x8868;&#x8fbe;&#x6c34;&#x5e73;&#x548c;&#x610f;&#x4e49;&#x3002;</AbstractText><AbstractText Label="&#x65b9;&#x6cd5;">&#x6839;&#x636e;&#x75c5;&#x60c5;&#x5c06;86&#x4f8b;&#x624b;&#x8db3;&#x53e3;&#x75c5;&#x60a3;&#x513f;&#x5206;&#x4e3a;1&#x671f;&#x7ec4;&#xff08;19&#x4f8b;&#xff09;&#x548c;2&#x671f;&#x7ec4;&#xff08;67&#x4f8b;&#xff09;&#x3002;&#x91c7;&#x7528;ELISA&#x6cd5;&#x68c0;&#x6d4b;&#x5916;&#x5468;&#x8840;&#x8840;&#x6d46;&#x4e2d;&#x8840;&#x7ba1;&#x6d3b;&#x6027;&#x80a0;&#x80bd;&#x3001;&#x3b3;-&#x5e72;&#x6270;&#x7d20;&#xff08;IFN-&#x3b3;&#xff09;&#x548c;&#x767d;&#x7ec6;&#x80de;&#x4ecb;&#x7d20;-4&#xff08;IL-4&#xff09;&#x6d53;&#x5ea6;&#x3002;&#x6d41;&#x5f0f;&#x7ec6;&#x80de;&#x672f;&#x68c0;&#x6d4b;CD3<sup>+</sup>T&#x3001;CD4<sup>+</sup>T&#x3001;CD8<sup>+</sup>T&#x6dcb;&#x5df4;&#x7ec6;&#x80de;&#x4e9a;&#x7fa4;&#x3002;RTPCR&#x6cd5;&#x5b9a;&#x6027;&#x68c0;&#x6d4b;&#x5927;&#x4fbf;&#x80a0;&#x9053;&#x75c5;&#x6bd2;71&#x578b;&#xff08;EV71&#xff09;-RNA&#x3002;</AbstractText><AbstractText Label="&#x7ed3;&#x679c;">2&#x671f;&#x7ec4;EV71-RNA&#x9633;&#x6027;&#x7387;&#x660e;&#x663e;&#x9ad8;&#x4e8e;1&#x671f;&#x7ec4;&#xff08;<i>P</i> &lt; 0.05&#xff09;&#xff1b;2&#x671f;&#x7ec4;&#x8840;&#x6e05;IgG&#x3001;IgA&#x3001;IgM&#x3001;&#x8865;&#x4f53;C3&#x6c34;&#x5e73;&#x9ad8;&#x4e8e;1&#x671f;&#x7ec4;&#xff08;<i>P</i> &lt; 0.05&#xff09;&#xff1b;2&#x671f;&#x7ec4;&#x5916;&#x5468;&#x8840;CD3<sup>+</sup>T&#x3001;CD4<sup>+</sup>T&#x3001;CD8<sup>+</sup>T&#x6dcb;&#x5df4;&#x7ec6;&#x80de;&#x4e9a;&#x7fa4;&#x6bd4;&#x4f8b;&#x4f4e;&#x4e8e;1&#x671f;&#x7ec4;&#xff08;<i>P</i> &lt; 0.05&#xff09;&#xff1b;2&#x671f;&#x7ec4;&#x5916;&#x5468;&#x8840;B&#x7ec6;&#x80de;&#x6bd4;&#x4f8b;&#x9ad8;&#x4e8e;1&#x671f;&#x7ec4;&#xff08;<i>P</i> &lt; 0.05&#xff09;&#xff1b;2&#x671f;&#x7ec4;CD4<sup>+</sup>/CD8<sup>+</sup>&#x6bd4;&#x503c;&#x4f4e;&#x4e8e;1&#x671f;&#x7ec4;&#xff08;<i>P</i> &lt; 0.05&#xff09;&#xff1b;2&#x671f;&#x7ec4;&#x5916;&#x5468;&#x8840;&#x8840;&#x7ba1;&#x6d3b;&#x6027;&#x80a0;&#x80bd;&#x6d53;&#x5ea6;&#x4f4e;&#x4e8e;1&#x671f;&#x7ec4;&#xff08;<i>P</i> &lt; 0.05&#xff09;&#x3002;86&#x4f8b;&#x624b;&#x8db3;&#x53e3;&#x75c5;&#x60a3;&#x513f;&#x5916;&#x5468;&#x8840;&#x8840;&#x7ba1;&#x6d3b;&#x6027;&#x80a0;&#x80bd;&#x6d53;&#x5ea6;&#x4e0e;CD4<sup>+</sup>T&#x6dcb;&#x5df4;&#x7ec6;&#x80de;&#x4e9a;&#x7fa4;&#x6bd4;&#x4f8b;&#x4ee5;&#x53ca;CD4<sup>+</sup>/CD8<sup>+</sup>&#x6bd4;&#x503c;&#x5448;&#x6b63;&#x76f8;&#x5173;&#xff08;&#x5206;&#x522b;<i>r</i>=0.533&#x3001;0.532&#xff0c;<i>P</i> &lt; 0.05&#xff09;&#x3002;</AbstractText><AbstractText Label="&#x7ed3;&#x8bba;">&#x8840;&#x7ba1;&#x6d3b;&#x6027;&#x80a0;&#x80bd;&#x53ef;&#x80fd;&#x662f;&#x53cd;&#x6620;&#x624b;&#x8db3;&#x53e3;&#x75c5;&#x4e25;&#x91cd;&#x7a0b;&#x5ea6;&#x7684;&#x91cd;&#x8981;&#x6807;&#x8bb0;&#x7269;&#x3002;</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>11</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27817774</ArticleId><ArticleId IdType="pmc">PMC7389850</ArticleId><ArticleId IdType="pii">10.7499/j.issn.1008-8830.2016.11.010</ArticleId><ArticleId IdType="doi">10.7499/j.issn.1008-8830.2016.11.010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Delgado M, Ganea D. Vasoactive intestinal peptide:a neuropeptide with pleiotropic immune functions. Amino Acids. 2013;45(1):25&#x2013;39. doi: 10.1007/s00726-011-1184-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-011-1184-8</ArticleId><ArticleId IdType="pmc">PMC3883350</ArticleId><ArticleId IdType="pubmed">22139413</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraccaroli L, Grasso E, Hauk V, et al. Defects in the vasoactive intestinal peptide (VIP)/VPAC system during early stages of the placental-maternal leucocyte interaction impair the maternal tolerogenic response. Clin Exp Immunol. 2012;170(3):310&#x2013;320. doi: 10.1111/cei.2012.170.issue-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.2012.170.issue-3</ArticleId><ArticleId IdType="pmc">PMC3518891</ArticleId><ArticleId IdType="pubmed">23121672</ArticleId></ArticleIdList></Reference><Reference><Citation>Padua D, Vu JP, Germano PM, et al. The role of neuropeptides in mouse models of colitis. J Mol Neurosci. 2016;59(2):203&#x2013;210. doi: 10.1007/s12031-015-0688-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-015-0688-1</ArticleId><ArticleId IdType="pmc">PMC4884658</ArticleId><ArticleId IdType="pubmed">26646243</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x5f90; &#x6881;, &#x5f20; &#x80b2;&#x624d;, &#x738b; &#x6590;, et al. &#x8840;&#x7ba1;&#x6d3b;&#x6027;&#x80a0;&#x80bd;&#x548c;&#x7532;&#x6cfc;&#x5c3c;&#x9f99;&#x5bf9;&#x5185;&#x6bd2;&#x7d20;&#x6027;&#x4f11;&#x514b;&#x5927;&#x9f20;&#x80a0;&#x9053;Toll&#x6837;&#x53d7;&#x4f53;mRNA&#x8868;&#x8fbe;&#x7684;&#x5f71;&#x54cd;. &#x4e2d;&#x56fd;&#x5c0f;&#x513f;&#x6025;&#x6551;&#x533b;&#x5b66;. 2013;20(2):149&#x2013;152.</Citation></Reference><Reference><Citation>&#x4e2d;&#x534e;&#x4eba;&#x6c11;&#x5171;&#x548c;&#x56fd;&#x536b;&#x751f;&#x90e8; &#x624b;&#x8db3;&#x53e3;&#x75c5;&#x8bca;&#x7597;&#x6307;&#x5357;(2010&#x5e74;&#x7248;) http://www.cnki.com.cn/Article/CJFDTOTAL-YXLZ201202023.htm &#x56fd;&#x9645;&#x547c;&#x5438;&#x6742;&#x5fd7;. 2010;30(24):1473&#x2013;1475.</Citation></Reference><Reference><Citation>&#x536b;&#x751f;&#x90e8;&#x624b;&#x8db3;&#x53e3;&#x75c5;&#x4e34;&#x5e8a;&#x4e13;&#x5bb6;&#x7ec4; &#x80a0;&#x9053;&#x75c5;&#x6bd2;71&#x578b;(EV71)&#x611f;&#x67d3;&#x91cd;&#x75c7;&#x75c5;&#x4f8b;&#x4e34;&#x5e8a;&#x6551;&#x6cbb;&#x4e13;&#x5bb6;&#x5171;&#x8bc6;. http://group.medlive.cn/topic/18256 &#x4e2d;&#x534e;&#x513f;&#x79d1;&#x6742;&#x5fd7;. 2011;49(9):675&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x5218; &#x6620;&#x971e;. &#x91cd;&#x89c6;EV71&#x91cd;&#x75c7;&#x624b;&#x8db3;&#x53e3;&#x75c5;&#x53d1;&#x75c5;&#x673a;&#x5236;&#x53ca;&#x9632;&#x6cbb;&#x5bf9;&#x7b56;&#x7684;&#x7814;&#x7a76;. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_zhsyhlcbdx201306001 &#x4e2d;&#x534e;&#x5b9e;&#x9a8c;&#x548c;&#x4e34;&#x5e8a;&#x75c5;&#x6bd2;&#x5b66;&#x6742;&#x5fd7;. 2013;27(6):401&#x2013;402.</Citation></Reference><Reference><Citation>Li H, Li S, Zheng J, et al. Cerebrospinal fluid Th1/Th2 cytokine profiles in children with enterovirus 71-associated meningoencephalitis. Microbiol Immunol. 2015;59(3):152&#x2013;159. doi: 10.1111/mim.v59.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/mim.v59.3</ArticleId><ArticleId IdType="pubmed">25611005</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J, Wang Y, Gan X, et al. Serum cytokine profiles of children with human enterovirus 71-associated hand, foot, and mouth disease. J Med Virol. 2014;86(8):1377&#x2013;1385. doi: 10.1002/jmv.v86.8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.v86.8</ArticleId><ArticleId IdType="pubmed">24619468</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LC, Shyu HW, Chen SH, et al. Enterovirus 71 infection induces Fas ligand expression and apoptosis of Jurkat cells. J Med Virol. 2006;78(6):780&#x2013;786. doi: 10.1002/(ISSN)1096-9071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(ISSN)1096-9071</ArticleId><ArticleId IdType="pubmed">16628611</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x4ed8; &#x4e39;, &#x674e; &#x6210;&#x8363;, &#x4f55; &#x989c;&#x971e;, et al.  &#x80a0;&#x9053;&#x75c5;&#x6bd2;71&#x578b;&#x611f;&#x67d3;&#x60a3;&#x513f;&#x514d;&#x75ab;&#x529f;&#x80fd;&#x63a2;&#x8ba8;. http://www.cqvip.com/qk/90104x/200911/32162985.html &#x4e2d;&#x534e;&#x513f;&#x79d1;&#x6742;&#x5fd7;. 2009;47(11):829&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">20078993</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x59dc; &#x6d9b;, &#x674e; &#x53cc;&#x6770;, &#x6b27;&#x9633; &#x6587;&#x732e;, et al.  &#x624b;&#x8db3;&#x53e3;&#x75c5;&#x60a3;&#x513f;Th17&#x3001;CD4+CD25+&#x8c03;&#x8282;&#x6027;T&#x7ec6;&#x80de;&#x7684;&#x53d8;&#x5316;&#x53ca;&#x610f;&#x4e49;. http://www.cjcp.org/EN/Y2013/V15/I12/1113 &#x4e2d;&#x56fd;&#x5f53;&#x4ee3;&#x513f;&#x79d1;&#x6742;&#x5fd7;. 2013;15(12):1113&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">24342210</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x9646; &#x56fd;&#x5e73;, &#x6731; &#x542f;&#x9555;. &#x80a0;&#x9053;&#x75c5;&#x6bd2;71&#x578b;&#x611f;&#x67d3;&#x6240;&#x81f4;&#x5371;&#x91cd;&#x75c7;&#x624b;&#x8db3;&#x53e3;&#x75c5;&#x8bca;&#x6cbb;&#x4e2d;&#x7684;&#x4e00;&#x4e9b;&#x601d;&#x8003;. http://med.wanfangdata.com.cn/paper/detail/periodicalpaper_zhek201204002 &#x4e2d;&#x534e;&#x513f;&#x79d1;&#x6742;&#x5fd7;. 2012;50(4):244&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801222</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez C, Ortiz AM, Juarranz Y, et al. Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis. PLoS One. 2014;9(1):e85248. doi: 10.1371/journal.pone.0085248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0085248</ArticleId><ArticleId IdType="pmc">PMC3883710</ArticleId><ArticleId IdType="pubmed">24409325</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x8881; &#x5723;&#x798f;, &#x674e; &#x6d01;, &#x795d; &#x4f1f;&#x5b8f;. &#x80a0;&#x9053;&#x75c5;&#x6bd2;71&#x611f;&#x67d3;&#x624b;&#x8db3;&#x53e3;&#x75c5;&#x60a3;&#x513f;&#x5916;&#x5468;&#x8840;T&#x6dcb;&#x5df4;&#x7ec6;&#x80de;&#x4e9a;&#x7fa4;&#x53ca;&#x514d;&#x75ab;&#x7403;&#x86cb;&#x767d;&#x68c0;&#x6d4b;&#x7814;&#x7a76;. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201412099.htm &#x4e2d;&#x534e;&#x533b;&#x9662;&#x611f;&#x67d3;&#x5b66;&#x6742;&#x5fd7;. 2014;24(12):3112&#x2013;3114.</Citation></Reference><Reference><Citation>Delgado M, Abad C, Martinez C, et al. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med. 2001;7(5):563&#x2013;568. doi: 10.1038/87887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/87887</ArticleId><ArticleId IdType="pubmed">11329057</ArticleId></ArticleIdList></Reference><Reference><Citation>Vomhof-DeKrey EE, Haring JS, Dorsam GP. Vasoactive intestinal peptide receptor 1 is downregulated during expansion of antigen-specific CD8 T cells following primary and secondary Listeria monocytogenes infections. J Neuroimmunol. 2011;234(1-2):40&#x2013;48. doi: 10.1016/j.jneuroim.2011.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2011.02.002</ArticleId><ArticleId IdType="pmc">PMC3092857</ArticleId><ArticleId IdType="pubmed">21396722</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JM, Darlak KA, Southerland L, et al. VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice. PLoS One. 2013;8(5):e63381. doi: 10.1371/journal.pone.0063381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0063381</ArticleId><ArticleId IdType="pmc">PMC3664580</ArticleId><ArticleId IdType="pubmed">23723978</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JM, Hossain MS, Southerland L, et al. Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients. Blood. 2013;121(12):2347&#x2013;2351. doi: 10.1182/blood-2012-06-437640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-06-437640</ArticleId><ArticleId IdType="pmc">PMC3606069</ArticleId><ArticleId IdType="pubmed">23325838</ArticleId></ArticleIdList></Reference><Reference><Citation>Ipp H, Nkambule BB, Reid TD, et al. CD4+T cells in HIV infection show increased levels of expression of a receptor for vasoactive intestinal peptide, VPAC2. Immunol Res. 2014;60(1):11&#x2013;15. doi: 10.1007/s12026-014-8487-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-014-8487-2</ArticleId><ArticleId IdType="pubmed">24469917</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Cai C, Feng J, et al. Peripheral T lymphocyte subset imbalances in children with enterovirus 71-induced hand, foot and mouth disease. Virus Res. 2014;180:84&#x2013;91. doi: 10.1016/j.virusres.2013.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2013.11.021</ArticleId><ArticleId IdType="pubmed">24316007</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>